Treating refractory leukemias in childhood, role of clofarabine

Therapeutics and Clinical Risk Management

Volumn 4, Issue 2, 2008, Pages 327-336

  Harned, Theresa M ^a,b   Gaynon, Paul S ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b NONE   (United States)

Author keywords

Childhood; Clofarabine; Leukemia; Pediatric; Refractory

Indexed keywords

ALLOPURINOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; CLADRIBINE; CLOFARABINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; FLUDARABINE; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; HYDROCORTISONE; IDARUBICIN; IFOSFAMIDE; MITOXANTRONE; NAVELBINE; NELARABINE; PREDNISOLONE; RETINOIC ACID; RITUXIMAB; THIOTEPA; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; DNA REPAIR; DNA SYNTHESIS INHIBITION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEVER; HAND FOOT SYNDROME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERURICEMIA; HYPOTENSION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SIDE EFFECT; SURVIVAL TIME; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T CELL LEUKEMIA;

EID: 44049094565     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Aladjidi N, Auvrignon A, Leblanc T, et al. 2003. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol, 21:4377-85.
2. Arceci RJ, Sande J, Lange B, et al. 2005. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood, 106:1183-8.
3. Bader P, Hancock J, Kreyenberg H, et al. 2002. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia, 16:1668-72.
4. Bonate PL, Arthaud L, Cantrell WR Jr, et al. 2006. Discovery and development of clofarabine:a nucleoside analogue for treating cancer. Nat Rev Drug Discov, 5:855-63.
5. Bonate PL, Arthaud L, Stuhler J, et al. 2005. The distribution, metabolism, and elimination of clofarabine in rats. Drug Metab Dispos, 33:739-48. Bonate PL, Craig A, Gaynon P, et al. 2004. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol, 44:1309-22.
6. Burnett AK, Kell WJ, Goldstone AH, et al. 2006. The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial. ASH Annual Meeting Abstracts, 108:13.
7. Carson DA, Wasson DB, Esparza LM, et al. 1992. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc Natl Acad Sci, USA, 89:2970-4.
8. Castellino SM, Alonzo TA, Buxton A, et al. 2007. Outcomes in childhood AML in the absence of transplantation in first remission-Children's Cancer Group (CCG) studies 2891 and CCG 213. Pediatr Blood Cancer, Jan 24 [epub ahead of print].
9. Chessells JM. 1998. Relapsed lymphoblastic leukaemia in children:a continuing challenge. Br J Haematol, 102:423-38.
10. Chessells JM, Veys P, Kempski H, et al. 2003. Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol, 123:396-405.
11. Clolar® package insert.
12. Cooper T, Ayres M, Nowak B, et al. 2005. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol, 55:361-8.
13. Coustan-Smith E, Gajjar A, Hijiya N, et al. 2004. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia, 18:499-504.
14. Creutzig U, Zimmermann M, Lehrnbecher T, et al. 2006. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia:results of AML-BFM 98. J Clin Oncol, 24:4499-506.
15. Creutzig U, Zimmermann M, Ritter J, et al. 2005. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia, 19:2030-42.
16. Crist WM, Anderson JR, Meza JL, et al. 2001. Intergroup rhabdomyosarcoma study-IV:results for patients with nonmetastatic disease. J Clin Oncol, 19:3091-102.
17. Crooks GM, Sato JK. 1995. Ifosfamide and etoposide in recurrent childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol, 17:34-8.
18. Eapen M, Raetz E, Zhang MJ, et al. 2006. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood, 107:4961-7.
19. Eckert C, Biondi A, Seeger K, et al. 2001. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet, 358:1239-41.
20. Einsiedel HG, von Stackelberg A, Hartmann R, et al. 2005. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol, 23:7942-50.
21. Elion GB, Hitchings GH, Vanderwerff H. 1951. Antagonists of nucleic acid derivatives. VI. Purines. J Biol Chem, 192:505-18.
22. Faderl S, Gandhi V, Keating MJ, et al. 2005a. The role of clofarabine in hematologic and solid malignancies - development of a next-generation nucleoside analog. Cancer, 103:1985-95.
23. Faderl S, Gandhi V, O'Brien S, et al. 2005b. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood, 105:940-7.
24. Faderl S, Verstovsek S, Cortes J, et al. 2006. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood, 108:45-51.
25. Gandhi V, Kantarjian H, Faderl S, et al. 2003. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res, 9:6335-42.
26. Gandhi V, Plunkett W, Bonate PL, et al. 2006. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia:strategy for treatment. Clin Cancer Res, 12:4011-17.
27. Gaynon PS. 2005. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol, 131:579-87.
28. Gaynon PS, Harris RE, Altman AJ, et al. 2006. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy:Children's Oncology Group study CCG-1941. J Clin Oncol, 24:3150-6.
29. Gaynon PS, Qu RP, Chappell RJ, et al. 1998. Survival after relapse in childhood acute lymphoblastic leukemia:impact of site and time to first relapse - the Children's Cancer Group Experience. Cancer, 82:1387-95.
30. Genini D, Adachi S, Chao Q, et al. 2000. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood, 96:3537-43.
31. Gibson BE, Wheatley K, Hann IM, et al. 2005. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia, 19:2130-8.
32. Goulden N, Bader P, Van Der Velden V, et al. 2003. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol, 122:24-9.
33. Grovas A, Fremgen A, Rauck A, et al. 1997. The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer, 80:2321-32.
34. Hijiya N, Franklin J, Rytting M, et al. 2007. A phase I study of clofarabine in combination with cyclophosphamide and etoposide:a new regimen in pediatric patients with relapsed or refractory acute leukemia. Proc Am Soc Clin Oncol, 26:abstract #9529.
35. Hitchings GH, Elion GB, Falco EA, et al. 1950. Studies on analogs of purines and pyrimidines. Ann N Y Acad Sci, 52:1318-35.
36. Iqbal S, Lenz HJ. 2004. Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol, 54(Suppl 1): S32-39.
37. Jeha S, Gandhi V, Chan KW, et al. 2004. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood, 103:784-9.
38. Jeha S, Gaynon PS, Razzouk BI, et al. 2006a. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol, 24:1917-23.
39. Jeha S, Kantarjian H. 2007. Clofarabine for the treatment of acute lymphoblastic leukemia. Expert Rev Anticancer Ther, 7:113-118.
40. Jeha S, Razzouk B, Gaynon P, et al. 2006b. Clofarabine in children with refractory/relapsed acute leukemia: results of 2 phase ii open label studies. ASH Annual Meeting Abstracts, 108:4460.
41. Jemal A, Tiwari RC, Murray T, et al. 2004. Cancer statistics, 2004. CA Cancer J Clin, 54:8-29.
42. Kantarjian H, Gandhi V, Cortes J, et al. 2003a. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood, 102:2379-86.
43. Kantarjian HM, Gandhi V, Kozuch P, et al. 2003b. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol, 21:1167-73.
44. Kantarjian H, Jeha S, Gandhi V, et al. 2007. Clofarabine:Past, present, and future. Leuk Lymphoma, Aug 13:1-9 [epub ahead of print].
45. Kearns P, Michel G, Nelken B, et al. 2006. BIOV-111a European phase II trial of clofarabine (Evoltra) in refractroy and relapsed childhood acute ]ymphoblastic leukemia. Blood, 108:527a (abstract #1859).
46. Knechtli CJ, Goulden NJ, Hancock JP, et al. 1998. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood, 92:4072-9.
47. Kurtzberg J. 2007. The long and winding road of the clinical development of Nelarabine. Leuk Lymphoma, 48:1-2.
48. Levis M, Smith BD, Beran M, et al. 2005. A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition. ASH Annual Meeting Abstracts, 106:403.
49. Miser JS, Kinsella TJ, Triche TJ, et al. 1987. Ifosfamide with mesna uroprotection and etoposide:an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol, 5:1191-8.
50. Nguyen K, Cheng S-C, Raetz E, et al. 2006. Factors influencing survival after relapse from childhood ALL: A Children's Oncology Group study. ASH Annual Meeting Abstracts, 108:1855.
51. Parker WB, Shaddix SC, Chang CH, et al. 1991. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res, 51:2386-94.
52. Parker WB, Shaddix SC, Rose LM, et al. 1999. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-beta-D-ribofuranosyl)adenine in CEM cells. Mol Pharmacol, 55:515-20.
53. Plunkett W, Gandhi V. 2001. Purine and pyrimidine nucleoside analogs. Cancer Chemother Biol Response Modif 19:21-45.
54. Pollard JA, Alonzo TA, Gerbing RB, et al. 2006. FLT3 internal tandem duplication in CD34+/CD33-precursors predicts poor outcome in acute myeloid leukemia. Blood, 108:2764-9.
55. Powell BL, Moser B, Stock W, et al. 2006. Preliminary results from the North American Acute Promyelocytic Leukemia (APL) study C9710. ASH Annual Meeting Abstracts, 108:566.
56. Powell B, Moser B, Stock W, et al. 2007. Effect of consolidation with arsenic trioxide (As 2 O 3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL):North American Intergroup Protocol C9710. Proc Am Soc Clin Oncol, 26:2.
57. Pui, C.H, Jeha, S. 2005b. Clofarabine. Nat Rev Drug Discov, (Suppl): S12-13.
58. Pui CH, Jeha S, Kirkpatrick P. 2005 a. Clofarabine. Nat Rev Drug Discov, 4:369-70.
59. Raetz EA, Borowitz MJ, Devidas M, et al. 2006. Outcomes of children with first marrow relapse: Results from Children's Oncology Group (COG) study AALL01P2. ASH Annual Meeting Abstracts, 108:1871.
60. Reinhardt D, Diekamp S, Fleischhack G, et al. 2004. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia. Onkologie. 27:269-72.
61. Schein PS. 2001. The case for a new national program for the development of cancer therapeutics. J Clin Oncol, 19:3142-53.
62. Schultz KR, Pullen DJ, Sather HN, et al. 2007. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia:a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood, 109:926-35.
63. Sievers EL, Larson RA, Stadtmauer EA, et al. 2001. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol, 19:3244-54.
64. Skipper HE, Thomson JR, Elion GB, et al. 1954. Observations on the anti-cancer activity of 6-mercaptopurine. Cancer Res, 14:294-8.
65. Tallman MS. 2006. New agents for the treatment of acute myeloid leukemia. Best Pract Res Clin Haematol, 19:311-20.
66. Webb DK. 1999. Management of relapsed acute myeloid leukaemia. Br J Haematol, 106:851-9.
67. Wells RJ, Adams MT, Alonzo TA, et al. 2003. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol, 21:2940-7.
68. Xie C, Plunkett W. 1995. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res, 55:2847-52.
69. Xie KC, Plunkett W. 1996. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. Cancer Res, 56:3030-7.
70. Yamauchi T, Nowak BJ, Keating MJ, et al. 2001. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res, 7:3580-9.
71. Zwaan CM, Reinhardt D, Corbacioglu S, et al. 2003. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/ refractory acute myeloid leukemia treated on compassionate-use basis. Blood, 101:3868-71.